News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Iroko Pharmaceuticals's Submicron NSAIDs Demonstrate Efficacy at Lower Doses in Studies in Patients With Acute and Chronic Pain


4/12/2013 9:47:46 AM

PHILADELPHIA--(BUSINESS WIRE)--Iroko Pharmaceuticals, LLC, a Philadelphia-based pharmaceutical company focused on the development and commercialization of innovative therapeutic products, is presenting positive Phase 3 data from its investigational submicron non-steroidal anti-inflammatory drug (NSAID) pipeline at two medical meetings. These presentations summarize the results of studies of lower dose submicron indomethacin in patients with post surgical pain, and lower dose submicron diclofenac in patients with osteoarthritis pain. Both studies met their primary endpoints of providing significant pain relief compared with placebo.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES